Start here if you're new
what it is
Amcor makes the bags, pouches, films, and containers that move food, drinks, and consumer goods through your life.
how it gets paid
Last year Amcor made $15.0B in revenue. bags was the main engine at $3.9B, or 26% of sales.
why it's growing
Treat 49% FY revenue as M&A / FX / presentation noise until you match the filing—Amcor does not double organically every year. The clean check here is EPS ~$0.95 vs ~$0.70 expected in this print.
what just happened
Quarterly revenue is on the order of ~$3.8B (≈¼ of ~$15B FY)—not $11.2B as a single quarter. EPS ~$0.95 vs ~$0.70 in this feed.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
65/100 earnings predictability — reasonably predictable
30.1x trailing p/e — you're paying up for this one
5.6% dividend yield — cash in your pocket every quarter
8.0% return on capital — typical for large-scale packaging
xvary composite: 56/100 — below average
What they do
Amcor makes the bags, pouches, films, and containers that move food, drinks, and consumer goods through your life.
Packaging is boring until you try replacing it across 210 facilities in 36 countries. That scale matters because your customer needs the same pouch or bottle to show up everywhere, every time. Return on capital (profit from money invested) is 8.0%, which tells you this is a scale business, not a magic business.
How they make money
$15.0B
annual revenue · vs. prior year % is distorted by M&A/FX—use the 10-K bridge, not a headline alone
bags
$3.9B
see filing
shrink films
$2.6B
pouches
$3.0B
paper and cardboard packaging
$2.7B
plastic rigid packaging
$2.8B
The products that matter
bags, pouches, films
flexible packaging
$10.1B · 67% of revenue
this is the $10.1B center of gravity at 67% of revenue (segment roll-up in the filing). bags + shrink + pouches on this page sum to about $9.5B—not a math error; sub-rows do not have to foot to the segment total one-for-one.
core segment
bottles, containers, closures
rigid packaging
$4.9B · 33% of revenue
this $4.9B segment supplies one-third of revenue and broadens your exposure across beverage and healthcare packaging. It is smaller than flexible, but too large to dismiss as a side business.
one-third of sales
Key numbers
5.6%
dividend yield
You are getting paid while you wait, which matters more when the 18-month price target sits below the current stock price.
30.1x
trailing p/e
Trailing p/e (stock price divided by past earnings) tells you investors are paying up for a business with 8.0% return on capital.
$14.6B
long-term debt
Debt equals 40% of capital, which means a lot of the balance sheet is already spoken for.
16.0%
operating margin
Operating margin (profit after running the business) shows Amcor keeps $0.16 from each $1 of sales before interest and taxes.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 2 — safer than 80% of stocks
- price stability 90 / 100
- long-term debt $14.6B (40% of capital)
- net profit margin 7.2% — keeps 7 cents of every dollar in revenue
- return on equity 14% — $0.14 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in AMCR 3 years ago → it's now worth $10,060.
The index would have given you $14,540.
source: institutional data · total return
What just happened
beat estimates
Quarterly revenue near ~$3.8B and EPS ~$0.95, ahead of the ~$0.70 estimate.
Drop $11.2B and triple-digit vs. prior year claims as “quarterly”—they do not sit against ~$15B FY. Gross margin 19.3% is the margin-discipline read.
~$3.8B
Q revenue (approx.)
$0.95
eps
19.3%
gross margin
the number that mattered
The key number was ~$0.95 vs ~$0.70 EPS—execution vs a packaging multiple, not mislabeled $11.2B “quarter” revenue.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is resin and polymer costs rising faster than Amcor can pass them through.
med
resin and polymer cost inflation
Raw materials account for 60–70% of costs. With an 18.9% gross margin and a 6.3% net margin, you do not need a dramatic input spike to pressure earnings.
This risk hits the exact cash flow supporting the 5.6% dividend.
med
plastic regulation and redesign costs
Single-use plastic rules, recycling mandates, and customer sustainability demands all land on a company selling a lot of packaging. This page does not quantify the cost, so the honest answer is that the exposure is real and the precision is thin.
If compliance or redesign spending rises, 6.3 cents of profit per sales dollar does not give you much shock absorption.
med
customer concentration
The top 10 customers represent about 30% of sales. That does not mean one contract loss breaks the story. It does mean large customer decisions matter more than the product catalog suggests.
Lost volume would hurt operating leverage faster than the headline revenue change implies.
when raw materials are 60–70% of costs and you keep 6.3% of sales as profit, pricing lag becomes the whole story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
net margin around 6.3%
This is the fulcrum. If margin slips below that level, the yield story gets less comfortable fast.
earnings
next quarterly results
Results are expected may 2026. You care less about a small revenue beat than whether profitability stays intact.
risk
raw material price trends
Track resin and polymer costs. If inputs rise faster than pricing, gross margin gets squeezed first and net margin follows.
trend
what the new cfo does with debt
Stephen R. Scherger stepped in during oct 2025. With $14.6B of long-term debt, financing choices matter almost as much as packaging demand.
Analyst rankings
short-term outlook
below average
momentum score 4 — analysts expect below-average price performance in the year ahead. in human-speak: they see income, not a catalyst.
risk profile
above average
stability score 2 — safer than roughly 80% of stocks. boring can be a feature when you are being paid 5.6% to wait.
chart momentum
bottom 5%
technical score 5 — the weakest ranking. The chart says investors have preferred almost anything with more growth.
earnings predictability
65 / 100
Decent, not perfect. The business is stable, but low margins still leave room for earnings disappointment.
source: institutional data
Institutional activity
298 buyers vs. 312 sellers in 4q2025. total institutional holdings: 0.3B shares.
source: institutional data
Price targets
3-5 year target range
$33
$57
$48
current price
$45
target midpoint · 7% from current · 3-5yr high: $70 (+45% · 14% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive